US › Healthcare

LENZ Therapeutics Inc (LENZ)

US · Healthcare · Biotechnology

$5.05+1.10%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.9M
Net profit
$-41.5M
Profit YoY
-183.8%
EPS
$-0.53
EPS estimate
$-1.21
Net margin
-2,182.4%

EPS came in at -0.53 against a street estimate of -1.21 — a beat of 56.2%.

Key statistics

Market cap
$166.2M
Forward P/E
0.0
P/B
0.67
Book value
$7.86
EPS (TTM)
$-3.64
52-week high
$50.40
52-week low
$4.68
50-day MA
$6.17
200-day MA
$14.65
Beta
1.62

Analyst view

Analysts rate LENZ Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $32.00.

Shareholding

Insiders
2.65%
Institutions
111.02%

Largest institutional holders

FundStake
RA Capital Management, LLC13.33%
Alpha Wave Global LP11.52%
FMR Inc11.47%
Versant Venture Management LLC8.47%
BlackRock Inc6.30%
Squarepoint Ops LLC4.80%
Aberdeen Group PLC3.69%
Franklin Resources Inc3.51%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for LENZ Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.